Skip to main content

The Globe and Mail

Concordia taps former Sagent Pharmaceuticals as new CEO

Drug company Concordia International Corp. has appointed former Sagent Pharmaceuticals chief executive Allan Oberman as its new chief executive, effective Nov. 14.

iStockPhoto

Drug company Concordia International Corp. has appointed former Sagent Pharmaceuticals chief executive Allan Oberman as its new chief executive, effective Nov. 14.

He succeeds Mark Thompson, who will also step down as chairman of Concordia's board of directors. The company announced in October that Thompson would be leaving after a replacement was found.

Oberman has more than 16 years experience in the pharmaceutical industry including at Sagent, an Illinois-based specialty drug company.

Story continues below advertisement

Under his leadership, Sagent was sold to Japan's largest generic drug manufacturer, Nichi-Iko Pharmaceutical Co. Ltd.

Oberman joined the Concordia board in October, as the company concluded a strategic review of options that was announced in April.

Thompson's role as chairman of Concordia's board will be filled by Jordan Kupinsky, who has been the board's lead independent director and a member of the board since 2013.

Report an error
Comments

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨

Combined Shape Created with Sketch.

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at privacy@globeandmail.com.